UBS AM’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $63.1M | Sell |
119,206
-21,601
| -15% | -$9.97M | 0.01% | 604 |
|
|
2026
Q1 | $67.6M | Buy |
140,807
+23,548
| +20% | +$12.1M | 0.01% | 574 |
|
|
2025
Q4 | $65.9M | Buy |
117,259
+37,795
| +48% | +$21.5M | 0.01% | 564 |
|
|
2025
Q3 | $40.9M | Sell |
79,464
-21,979
| -22% | -$9.6M | 0.01% | 639 |
|
|
2025
Q2 | $31.8M | Buy |
101,443
+19,626
| +24% | +$5.89M | 0.01% | 860 |
|
|
2025
Q1 | $24.9M | Buy |
81,817
+3,010
| +4% | +$1.01M | 0.01% | 869 |
|
|
2024
Q4 | $26.2M | Sell |
78,807
-4,628
| -6% | -$1.57M | 0.01% | 849 |
|
|
2024
Q3 | $27.9M | Sell |
83,435
-60,713
| -42% | -$23.1M | 0.01% | 826 |
|
|
2024
Q2 | $59.4M | Buy |
144,148
+29,432
| +26% | +$11.7M | 0.02% | 573 |
|
|
2024
Q1 | $46.4M | Sell |
114,716
-503
| -0.4% | -$177K | 0.02% | 612 |
|
|
2023
Q4 | $35.3M | Sell |
115,219
-76
| -0.1% | -$20.5K | 0.01% | 659 |
|
|
2023
Q3 | $27.9M | Sell |
115,295
-77,567
| -40% | -$19.8M | 0.01% | 692 |
|
|
2023
Q2 | $36.3M | Hold |
192,862
| – | – | 0.02% | 637 |
|
|
2023
Q1 | $36.3M | Buy |
+192,862
| New | +$39.9M | 0.02% | 637 |
|
|
2022
Q4 | – | Sell |
-122,175
| Closed | -$19.2M | – | 2666 |
|
|
2022
Q3 | $19.2M | Sell |
122,175
-17,758
| -13% | -$2.83M | 0.01% | 769 |
|
|
2022
Q2 | $20.9M | Sell |
139,933
-1,013
| -0.7% | -$147K | 0.01% | 725 |
|
|
2022
Q1 | $23.1M | Sell |
140,946
-6,744
| -5% | -$1.11M | 0.01% | 811 |
|
|
2021
Q4 | $32.1M | Sell |
147,690
-196
| -0.1% | -$41K | 0.01% | 777 |
|
|
2021
Q3 | $28M | Sell |
147,886
-1,980
| -1% | -$361K | 0.01% | 779 |
|
|
2021
Q2 | $26.5M | Sell |
149,866
-7,533
| -5% | -$1.3M | 0.01% | 811 |
|
|
2021
Q1 | $25.8M | Sell |
157,399
-428
| -0.3% | -$65.5K | 0.01% | 795 |
|
|
2020
Q4 | $22M | Sell |
157,827
-6,091
| -4% | -$768K | 0.01% | 828 |
|
|
2020
Q3 | $18.3M | Buy |
163,918
+133,539
| +440% | +$15.4M | 0.01% | 790 |
|
|
2020
Q2 | $2.83M | Sell |
30,379
-448
| -1% | -$38.1K | ﹤0.01% | 1377 |
|
|
2020
Q1 | $2.26M | Buy |
30,827
+2,124
| +7% | +$184K | ﹤0.01% | 1356 |
|
|
2019
Q4 | $2.41M | Buy |
28,703
+628
| +2% | +$48.6K | ﹤0.01% | 1513 |
|
|
2019
Q3 | $2.36M | Buy |
28,075
+7,237
| +35% | +$547K | ﹤0.01% | 1533 |
|
|
2019
Q2 | $1.36M | Buy |
20,838
+1,768
| +9% | +$102K | ﹤0.01% | 1765 |
|
|
2019
Q1 | $1.12M | Buy |
19,070
+420
| +2% | +$25.1K | ﹤0.01% | 1783 |
|
|
2018
Q4 | $987K | Buy |
18,650
+7,050
| +61% | +$387K | ﹤0.01% | 1764 |
|
|
2018
Q3 | $695K | Buy |
+11,600
| New | +$635K | ﹤0.01% | 1948 |
|
Other funds holding MEDP
WA
UBS AM's MEDP Position: Q2 2026 in Review
UBS AM reduced its Medpace (MEDP) stake by 15% in Q2 2026, selling an estimated $9.97M and leaving 119,206 shares worth $63.1M. The position accounts for 0.01% of the portfolio, ranked #604.
UBS AM first reported a position in MEDP in Q3 2018 and has held it in 31 quarters since. The position peaked at $67.6M in Q1 2026. 694 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.
- UBS AM held 119,206 shares of Medpace worth $63.1M as of Q2 2026.
- UBS AM sold 21,601 Medpace shares in Q2 2026, an estimated $9.97M.
- Medpace made up 0.01% of UBS AM's portfolio in Q2 2026, its #604 holding.
- UBS AM first reported a position in Medpace in Q3 2018 and has held it in 31 quarters since.
- UBS AM's Medpace position peaked at $67.6M in Q1 2026.
- 694 funds tracked by Wall St. Rank held Medpace as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.